Process for the preparation of 7-substituted-3 quinolinecarbonitriles
申请人:Wyeth Holdings Corporation
公开号:US20030212276A1
公开(公告)日:2003-11-13
There is provided a process for the preparation of 7-substituted-3-quinolinecarbonitriles and intermediates useful in a process to prepare 7-substituted-3-quinolinecarbonitriles and pharmaceutically acceptable salts is described. Where 7-fluoro-4-oxo-1,4-dihydro-3-quinolinecarbonitrile is converted in three steps to 7-substituted-3-quinolinecarbonitriles which inhibit the action of certain protein kinases and are useful in the treatment of cancer.
[EN] PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES<br/>[FR] PREPARATION DE 3-QUINOLINE ET DE 3-QUINOL- 4-ONE CARBONITRILES SUBSTITUES EN POSITION 7
申请人:WYETH CORP
公开号:WO2003093241A1
公开(公告)日:2003-11-13
There is provided a process for the preparation of 7-substituted-3-quinolinecarbonitriles and intermediates useful in a process to prepare 7-substituted-3-quinolinecarbonitriles and pharmaceutically acceptable salts is described. Where 7-fluoro-4-oxo-1,4-dihydro-3-quinolinecarbonitrile is converted in three steps to 7-substituted-3-quinolinecarbonitriles which inhibit the action of certain protein kinases and are useful in the treatment of cancer.
Compounds are provided having utility for the treatment of viral infections, particularly HCV.
提供了化合物,可用于治疗病毒感染,尤其是HCV。
Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease
申请人:Merck Sharp & Dohme Corp.
公开号:US10414774B2
公开(公告)日:2019-09-17
Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.
本文描述的是式(I)化合物或其药学上可接受的盐。式 I 的化合物作为 Cyp8b1 抑制剂,可用于预防、治疗或作为糖尿病和心血管疾病的补救药物。